DHCR7表达预测脓毒症不良结局与死亡
该研究对前瞻性纳入的脓毒症患者(急诊科或ICU,首24小时)样本进行脂质代谢基因表达分析,并利用斑马鱼内毒素血症模型验证。发现胆固醇代谢基因DHCR7在推导队列(96例)和验证队列(52例)的不良结局脓毒症患者中显著上调,在90天非幸存者中亦上调(仅验证队列)。斑马鱼模型显示dhcr7及多个脂质基因上调,6种脂质相关药物中仅Dhcr7抑制剂AY9944在100%致死性模型中完全挽救斑马鱼。作者结论为DHCR7上调与不良结局相关,需外部验证,该通路可能作为治疗靶点。
要点
- 在推导队列(96例)和验证队列(52例)中,DHCR7在不良结局脓毒症患者中较快速恢复患者显著上调。
- 验证队列中,DHCR7在90天非幸存者中亦显著上调。
- 斑马鱼脓毒症模型显示dhcr7及dhcr24、sqlea、cyp51、msmo1、ldlra等基因较对照上调。
- 6种脂质相关药物中,仅Dhcr7抑制剂AY9944在100%致死性斑马鱼内毒素血症模型中完全挽救死亡。
- 作者结论:DHCR7上调需外部验证,该通路可能作为改善脓毒症结局的潜在治疗靶点。
适用人群与场景
- 前瞻性纳入的脓毒症患者,样本取自急诊科或ICU,首24小时内。
- 推导队列96例:12例早期死亡(14天内)、13例慢性危重症、51例快速恢复、20例对照。
- 验证队列52例:6例早期死亡、8例慢性危重症、38例快速恢复。
研究设计与关键结果
- 研究类型:对前瞻性纳入的脓毒症患者样本进行二次分析,并使用斑马鱼内毒素血症模型进行药物发现;患者来自城市教学医院的急诊科或ICU。
- 推导队列96例(12例早期死亡、13例慢性危重症、51例快速恢复、20例对照),验证队列52例(6例早期死亡、8例慢性危重症、38例快速恢复)。
- 胆固醇代谢基因7-脱氢胆固醇还原酶(DHCR7)在推导队列和验证队列中,不良结局脓毒症患者较快速恢复患者显著上调;在90天非幸存者中亦显著上调(仅验证队列),并经RT-qPCR验证。
- 斑马鱼脓毒症模型显示dhcr7及dhcr24、sqlea、cyp51、msmo1、ldlra等基因较对照上调。
- 测试6种脂质相关药物,仅Dhcr7抑制剂AY9944在100%致死性斑马鱼内毒素血症模型中完全挽救斑马鱼免于死亡。
证据类型、等级与局限
- 证据类型:对前瞻性队列样本的二次分析及斑马鱼实验研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为DHCR7上调需外部验证,该通路可能作为改善脓毒症结局的潜在治疗靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: This is a study of lipid metabolic gene expression patterns to discover precision medicine for sepsis.
OBJECTIVES: Sepsis patients experience poor outcomes including chronic critical illness (CCI) or early death (within 14 d). We investigated lipid metabolic gene expression differences by outcome to discover therapeutic targets.
DESIGN SETTING AND PARTICITPANTS: Secondary analysis of samples from prospectively enrolled sepsis patients (first 24 hr) and a zebrafish endotoxemia model for drug discovery. Patients were enrolled from the emergency department or ICU at an urban teaching hospital. Enrollment samples from sepsis patients were analyzed. Clinical data and cholesterol levels were recorded. Leukocytes were processed for RNA sequencing and reverse transcriptase polymerase chain reaction. A lipopolysaccharide zebrafish endotoxemia model was used for confirmation of human transcriptomic findings and drug discovery.
MAIN OUTCOMES AND MEASURES: The derivation cohort included 96 patients and controls (12 early death, 13 CCI, 51 rapid recovery, and 20 controls) and the validation cohort had 52 patients (6 early death, 8 CCI, and 38 rapid recovery).
RESULTS: The cholesterol metabolism gene 7-dehydrocholesterol reductase (DHCR7) was significantly up-regulated in both derivation and validation cohorts in poor outcome sepsis compared with rapid recovery patients and in 90-day nonsurvivors (validation only) and validated using RT-qPCR analysis. Our zebrafish sepsis model showed up-regulation of dhcr7 and several of the same lipid genes up-regulated in poor outcome human sepsis (dhcr24, sqlea, cyp51, msmo1, and ldlra) compared with controls. We then tested six lipid-based drugs in the zebrafish endotoxemia model. Of these, only the Dhcr7 inhibitor AY9944 completely rescued zebrafish from lipopolysaccharide death in a model with 100% lethality.
CONCLUSIONS: DHCR7, an important cholesterol metabolism gene, was up-regulated in poor outcome sepsis patients warranting external validation. This pathway may serve as a potential therapeutic target to improve sepsis outcomes.
参考来源
- Guirgis FW, Jacob V, Wu D, et al. DHCR7 Expression Predicts Poor Outcomes and Mortality From Sepsis. Crit Care Explor. 2023. PMID: 37332366. doi:10.1097/CCE.0000000000000929
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。